Panel of Bloodstream MicroRNAs Predicts Damage from Radiation Exposure
|
By LabMedica International staff writers Posted on 25 May 2015 |
A panel of microRNAs (miRNAs) that can be measured in blood samples is able to predict the extent of long-term radiation injury and likelihood of survival following exposure to high doses of radiation.
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Latest Pathology News
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read moreMicrobiology
view channel
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Project Aims to Develop First Single-Cell Assay for ADC Therapies
Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more




.jpg)



